FDCA busts anxiety drug production racket

Ahmedabad:  The state Food and Drugs Control Administration (FDCA) on Thursday busted a racket involved in the illegal production and sale of bulk drug pregabalin across Ahmedabad and Ankleshwar. Pregabalin is a key active pharmaceutical ingredient (API) used in medications to treat neuropathic pain, epilepsy and generalised anxiety disorder.

The crackdown revealed that Estime Enterprise in Ahmedabad was trading the API without a valid licence. Evidence found at their premises indicated the sales of approximately 4,300kg of pregabalin worth around Rs 85 lakh. The investigation led authorities to Axis Pharmachem in Ankleshwar and Iconic Pharmachem in Panoli.

“Iconic Pharmachem was reportedly caught producing pregabalin in their chemical factory despite lacking the necessary drug manufacturing licence, while Axis Pharmachem was sealed for allegedly using its licence to facilitate sales from Iconic Pharmachem for a commission, without generating proper documents,” said FDCA commissioner H G Koshia.

“Nearly 1,000kg worth Rs 21.50 lakh was seized from Iconic Pharmachem in Panoli. A branch of Estime Enterprise in Bharuch was found to be selling pregabalin and other API chemicals without licences and generating their own test reports. From here, 35kg of pregabalin was seized,” Koshia said.

Individuals allegedly involved in this extensive scheme include Nimesh Shah and Harish Ashwin Joshi from Estime Enterprise, Pravin Patel from Axis Pharmachem, Bhavesh Chalodiya from Iconic Pharmachem and Lalit Raiyani from Biocrom Analytical Lab. The analytical lab, which operated without the required licence or legal documents, was found to have been providing test reports via WhatsApp.

Related Posts

  • Pharma
  • May 14, 2025
  • 104 views
DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

The Drugs Technical Advisory Board (DTAB) has directed the Central drug regulator to take up the matter related to withdrawal of product license for antibiotic fixed dose combinations (FDCs), which…

  • Pharma
  • May 14, 2025
  • 102 views
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India’s anti-obesity drug market has grown more than fourfold in the last five years fuelled by rising instances of lifestyle diseases along with greater affordability and willingness among a section…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

DTAB asks DCGI to take up withdrawal of license for certain FDC antibiotics with SLAs

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

3 held with 60,000 tramadol tablets

3 held with 60,000 tramadol tablets

Indian Pharma May See Limited Short-Term Impact from US Drug Pricing Order

Indian Pharma May See Limited Short-Term Impact from US Drug Pricing Order

Hip Hip No Hurray: Steroid Misuse Linked To Rising Damage In Youths

Hip Hip No Hurray: Steroid Misuse Linked To Rising Damage In Youths

Antibiotic use in infancy raises early puberty risk in girls, study finds

Antibiotic use in infancy raises early puberty risk in girls, study finds